Last updated: July 27, 2026
Litigation summary and analysis: Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited, 1:15-cv-00902 (D.N.J.)
Executive summary: The case Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited (U.S. District Court for the District of New Jersey, 1:15-cv-00902) is a patent infringement dispute tied to Aurobindo’s FDA generic/ANDA product and Bayer’s asserted IP portfolio. The docket reflects standard Hatch-Waxman litigation posture: an accused ANDA filing, infringement allegations against Bayer’s Orange Book-listed patents (or patent set tied to the reference drug), and responses including noninfringement/invalidity defenses. Final enforcement outcome, settlement terms, and which specific patents were adjudicated must be confirmed from the case docket and the patent list in the pleadings, because the record cannot be fully reconstructed from the limited information provided here.
Case: Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited
Court: U.S. District Court, District of New Jersey
Case number: 1:15-cv-00902
Party roles: Plaintiff Bayer Intellectual Property GmbH; Defendant Aurobindo Pharma Limited
Litigation framework: Hatch-Waxman Act (ANDA-related patent infringement)
What patents were asserted in Bayer v. Aurobindo 1:15-cv-00902, and which were the key infringement targets?
Featured-snippet answer: The asserted patents are the ones listed by Bayer in the Orange Book for the relevant branded reference product (and/or the patents Bayer tied to the ANDA submission). The exact patent numbers and claims are not available from the input provided, so the infringement targets cannot be enumerated accurately without the pleadings or Orange Book reference listing used in the complaint.
Patent estate scope: what typically shows up in this fact pattern
In Hatch-Waxman cases filed in 2015 by a Bayer IP entity against an ANDA filer, the asserted estate usually contains one or more of the following categories:
- Drug substance or drug product composition/formulation patents
- Method-of-use patents tied to dosing regimen or therapeutic use
- Manufacturing process patents
- Combination/dose-form patents (if the ANDA product is a fixed dose or specific strength)
How to identify the “key” patents in this docket
The key patents are usually those that:
- are listed as Orange Book patents for the brand drug,
- were the subject of the ANDA’s certification (Paragraph IV or other certification),
- drive the injunction request and any stipulated entry of judgment after settlement.
Because the exact asserted patent set is not contained in the information provided, any attempt to list them would be incomplete.
When was the litigation filed, and what does the timeline imply for exclusivity and FDA approval risk?
Featured-snippet answer: The case was filed in 2015 (as indicated by docket number and caption). A 2015 filing generally corresponds to a period when:
- A first wave of Paragraph IV ANDA certifications was met with immediate patent suit, and
- the brand holder sought automatic statutory stay and/or injunctive relief.
Timing signals that affect commercial exposure
In these cases, the operative timeline usually includes:
- ANDA submission date and the FDA acceptance/notification window
- Patent suit filing date relative to FDA action (and whether the statutory stay was triggered)
- Court schedule for claim construction and summary judgment
Without the docket entry history, the precise dates for each event (filing, amendments, Markman, summary judgment, trial, and final disposition) cannot be asserted.
Did the court grant a preliminary injunction or enter a final judgment in 1:15-cv-00902?
Featured-snippet answer: The case is a docketed matter in the District of New Jersey under the stated caption, but the provided input does not include the dispositive docket outcome. A reliable “granted/denied” determination requires the specific docket dispositions (orders and judgments), which are not provided here.
What outcomes typically determine business strategy
The business impact depends on whether the court:
- granted an automatic statutory stay through the timing of the suit (a common consequence of a timely Hatch-Waxman filing),
- issued a preliminary injunction after likelihood-of-success findings,
- entered final judgment after summary judgment or trial, or
- ended via settlement with a stipulated order and agreed launch/entry date.
Was this a Paragraph IV ANDA challenge, and how does that affect legal leverage?
Featured-snippet answer: The fact pattern implied by the caption and posture is consistent with an ANDA Paragraph IV challenge framework, where Aurobindo’s certification conflicts with Bayer’s Orange Book patents and triggers suit. The input does not state the certification type; therefore, the exact Paragraph IV status cannot be stated as fact.
Certification linkage: how leverage is constructed
In Hatch-Waxman litigation:
- the statutory stay risk is driven by the type of certification,
- the scope of damages and injunctive relief aligns with the claims found infringed (and whether patents are invalidated),
- and settlement leverage often tracks which patents remain “likely enforceable.”
Without the certification language (e.g., IV vs other), the leverage analysis cannot be tied to a definitive procedural posture.
Which companies and product(s) were at issue: reference drug, strength, dosage form, and geographic entry?
Featured-snippet answer: The case caption identifies Bayer Intellectual Property GmbH and Aurobindo Pharma Limited, but it does not identify the specific reference drug name, the ANDA product, or its strength/dosage form.
Why product identification matters
Product details determine:
- which Orange Book patents exist,
- which label and method-of-use claims are implicated,
- and which manufacturing/process patents are asserted.
Because the input contains no product identifier, those elements cannot be provided.
What is the Orange Book status of the asserted patents in this case?
Featured-snippet answer: Bayer’s asserted patents in Hatch-Waxman cases are typically Orange Book-listed for the reference product. This input does not include the Orange Book listing or patent table from the relevant NDA/BLA, so an accurate Orange Book status mapping cannot be produced.
What “status” usually includes in a useful litigation brief
A complete Orange Book status analysis normally includes:
- patent number
- expiration date
- patent type (drug substance, drug product, method of use)
- listed NDA and dosage form
- exclusivity expiration (whether patent-only vs additional exclusivity)
- remaining term at filing and at potential launch
Those items are not available here.
How strong is Bayer’s patent estate versus Aurobindo’s defenses in 1:15-cv-00902?
Featured-snippet answer: Strength cannot be quantified from the provided information because the asserted claims, validity record, and claim construction results are not included.
Typical defense patterns and what the court’s rulings would indicate
Patent litigation outcomes generally hinge on:
- claim construction breadth and whether limitation terms narrow the infringement theory
- §103 obviousness combining prior art references
- §102 novelty attacks on each element
- §112 enablement and written description challenges
- noninfringement based on ANDA product composition or manufacturing differences
A defensibility assessment requires the specific rulings from this case’s orders.
What patent litigation risks exist for Aurobindo: generic entry timing and design-around options?
Featured-snippet answer: The generic entry risk in these cases is determined by:
- which patents were found invalid or not infringed,
- which patents survived claim construction and dispositive motions,
- and whether the parties settled on an entry date or remained locked in appeals.
Those determinations are not in the provided input.
Business consequences by outcome type
- If key formulation or substance patents survive: higher risk of permanent injunction or delayed launch.
- If method-of-use patents are narrowed: design-around via labeling and patient population targeting can reduce infringement risk.
- If manufacturing-process patents are invalidated: scale-up and commercial manufacturing timelines become less constrained.
Did the case settle, and what would settlement typically control (entry date, royalties, license scope)?
Featured-snippet answer: Settlement or final disposition is not evidenced in the supplied information. A settlement summary must reflect the actual docket termination status and any stipulated dismissal orders or consent judgments.
What settlement terms usually control in Bayer v. generic ANDA disputes
When cases settle, agreements commonly address:
- a bottom-line launch date (earliest commercial sale)
- a carve-out for strengths or NDCs
- royalty or payment terms
- license scope for manufacturing and commercial distribution
- covenant-not-to-sue boundaries around remaining patents
These items require the actual settlement documentation or final docket entries.
What FDA regulatory status issues are implicated (ANDA approval, labeling carve-outs, and 505(b)(2) alternatives)?
Featured-snippet answer: The case is consistent with an ANDA-driven patent dispute affecting FDA approval/entry, but the input does not identify the FDA product approval status, whether FDA approval was granted, stayed, or delayed, or what labeling changes were negotiated.
Labeling and regulatory hooks that drive infringement risk
In ANDA cases, labeling can be the litigation pivot:
- method-of-use infringement allegations often depend on label text,
- design-around can be attempted via contraindications, dosing restrictions, or patient selection language,
- and labeling carve-outs often determine whether infringement theories remain viable after settlement.
How does this Bayer v. Aurobindo litigation compare with other Bayer IP vs generic defendant cases?
Featured-snippet answer: Comparative analysis requires the set of other cases and their outcomes. The provided input includes only the case identifier, not any cross-case citations, consolidation, or referenced prior art/patent themes.
What a comparison usually shows
- whether Bayer uses similar patent clusters across multiple generics,
- whether courts tend to uphold or invalidate the same patent types,
- and whether Aurobindo repeatedly targets specific claim categories.
Without additional case identifiers or outcome data, comparison cannot be substantiated.
Key takeaways
- Case: Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited, 1:15-cv-00902 (D.N.J.).
- Type: Hatch-Waxman-style patent infringement litigation tied to an ANDA market entry attempt.
- Patent and procedural specifics: The asserted patent numbers, Orange Book status, certifications, and final outcome are not present in the provided input, so they cannot be stated as facts here.
- Business impact: Entry and damages risk hinge on which patents survived validity/noninfringement defenses and whether the case ended in judgment or settlement with agreed launch dates.
FAQs
- Which Orange Book patents did Bayer list for the branded reference drug implicated by 1:15-cv-00902?
- Did Aurobindo’s ANDA certify under Paragraph IV, and what certification type was challenged?
- What claim construction terms drove infringement or invalidity arguments in this docket?
- What was the final case disposition (judgment, dismissal, or settlement), and what date controlled generic entry risk?
- Were any patents added or dropped via amended complaints, and did that change the case outcome?
References
- United States District Court, District of New Jersey. Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited, Case No. 1:15-cv-00902. (Docket and filings).
